Influenza Vaccine and Pneumococcal Vaccine

Immunogenicity and Safety of an Influenza Vaccine Administered Concomitantly With a 13-Valent Pneumococcal Conjugate Vaccine or 23-Valent Polysaccharide Pneumococcal Vaccine in Elderly Patients

Previous studies have demonstrated the immunogenicity and safety of the co-administration of the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide pneumococcal vaccine (PPV) or pneumococcal conjugate vaccine (PCV). However, there is no direct comparison study that evaluates the immunogenicity and safety of IIV3 given concomitantly with PCV13 or PPV23 in the elderly. This study is intended to compare the immunogenicity and safety of concomitant administration in the elderly subjects.

During the influenza vaccination period, 224 healthy elderly volunteers randomly received IIV3 given concomitantly with either PCV13 (PCV13+IIV3) or PPV23 (PPV23+IIV3) in a 1:1 ratio. Serum hemagglutination-inhibiting (HI) antibodies for IIV3 were measured at the time of vaccination and 1 month after vaccination. Adverse events were recorded prospectively in a clinical diary during a 7-day period.

Inclusion Criteria:

• Adults aged ≥65 years who signed the informed consent

Exclusion Criteria:

• Previous pneumococcal vaccine recipients
• Egg allergy
• History of serious adverse event after vaccination
• Any acute disease or infection
• History of neurological symptoms or signs
• Impairment of immune function or immunosuppressant use
• Bleeding diathesis
• Fever (defined as axillary temperature ³38.0°C) within 3 days
• History of Streptococcal pneumoniae infection within the previous 5 years